Printer Friendly

U.S. FDA APPROVES EXPANSION OF ZENECA PHARMACEUTICALS' ITALIAN ANESTHETICS FACTORY

 LONDON, April 19 /PRNewswire/ -- Zeneca Pharmaceuticals (formerly ICI) today announced it has received approval from the Food and Drug Administration to expand its production facility that supplies the injectable anesthetic "Diprivan"(TM) to the U.S. market.
 Diprivan is manufactured at the company's production facilities in Caponago, near Milan, Italy. FDA approval is required for all plants, including those outside the United States, that supply pharmaceutical products to the United States. In response to the growth of Diprivan for anesthesia and intensive care sedation, the Diprivan factory has received cumulative investment from Zeneca Pharma Italia totaling 60 million pounds sterling.
 The first Diprivan plant at Caponago, built at an original cost of 16 million pounds, was inaugurated in June 1991. A further investment program of 44 million pounds was announced last year to expand production facilities. Due for completion in 1994, this expansion involves new production facilities, packing, distribution, warehousing, site infrastructure and services, in addition to laboratories.
 Existing capacity will be almost doubled when the expansion is completed, and flexibility of meeting future market demand will thereby be increased.
 David Friend, chief executive officer of Zeneca Pharmaceuticals, said: "We are pleased that the FDA approval has underlined the importance of this factory as a source for world markets. The investment in Caponago further confirms our confidence in the product." Mr. Friend emphasized that these operations represented a significant step in strengthening Zeneca's European manufacturing base.
 Diprivan was launched in the United States in 1989 and had sales worldwide of over 140 million pounds in 1992. It is a leading agent in the anesthetics market.
 -0- 4/19/93
 /CONTACT: Jeffrey A. Soper of Zeneca Pharmaceuticals, 302-886-7433/


CO: Zeneca Pharmaceuticals ST: IN: MTC SU:

GK -- NY040 -- 7223 04/19/93 09:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 19, 1993
Words:293
Previous Article:ICI EXPLOSIVES ENVIRONMENTAL TO COMPLETE STUDY IN RUSSIA UNDER U.S. GOVERNMENT GRANT
Next Article:CHASE MANHATTAN CORPORATION PLACED ON RATING WATCH-FAVORABLE BY DUFF & PHELPS
Topics:


Related Articles
ZENECA ANNOUNCES NEW INDICATION FOR DIPRIVAN INJECTION
CIMA Announces Fast-Melt Development Program for Zeneca Migraine Treatment Zomig
FDA Advisory Panel Recommends Approval of Zeneca's NOLVADEX(R) (Tamoxifen Citrate) for Reduction of Incidence of Breast Cancer In Women at Increased...
Zeneca Pharmaceuticals Reports Study Shows CHIROCAINE(TM) (levobupivacaine HCl) Injection Efficacious In Major Abdominal Surgery.
Landmark Findings from Breast Cancer Prevention Trial Lead FDA to Approve Zeneca's NOLVADEX(R) (Tamoxifen Citrate) for the Reduction of Breast Cancer...
Zeneca Pharmaceuticals Pursuing 6-Month Extension of U.S. Marketing Exclusivity for Blockbuster Ace Inhibitor ZESTRIL(R) (lisinopril) Tablets; FDA...
Positive Recommendations From FDA Advisory Committee Meeting on Chirocaine.
Gensia Sicor Announces Court's Denial of Zeneca's Motion for Preliminary Injunction Against FDA.
Algos Pharmaceutical Announces First Quarter 1999 Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters